-
Tegileridine Fumarate Injection Approved for Marketing by China NMPA
2024-01-31
Recently, the Category 1 innovative product Tegileridine Fumarate Injection (trade name: 艾苏特) of Jiangsu Hengrui Pharmaceuticals Co., Ltd. was approved for marketing by China NMPA. It is indicated for moderate to severe pain after abdominal surgery.
-
Innovative TCM Ercha Shangqing Wan approved for marketing
2024-01-24
Recently, the Category 1.1 innovative traditional Chinese medicine (TCM) Ercha Shangqing Wan of Hubei Qijin Pharmaceutical Co Ltd was approved for marketing by China's National Medical Products Administration.
-
China's TCM institutions provide diagnoses, treatment to 1.28 bln people in 2023
2024-01-23
Traditional Chinese medicine (TCM) health care institutions provided diagnoses and treatment to an estimated 1.28 billion people across China in 2023, according to a national TCM meeting that opened on Monday.
-
Gastric Bypass Stent System Approved for Marketing
2024-01-17
Recently, the innovative product "Gastric Bypass Stent System" of Hangzhou Tongee Medical Technology Co., Ltd. was approved by China NMPA.
-
Ganagliflozin Proline Tablets Approved for Marketing by China NMPA
2024-01-19
Recently, the Category 1 innovative product Ganagliflozin Proline Tablets (trade name: 惠优静) of Jilin Huisheng Biopharmaceutical Co,. Ltd. was approved for marketing by China NMPA.
-
Lecanemab Injection Approved for Marketing by China NMPA
2024-01-09
Recently, the Lecanemab Injection (trade name: 乐意保/Leqembi) of Eisai Inc. was approved for marketing by China NMPA through the priority review and approval procedures. It is indicated for the treatment of mild cognitive impairment and dementia caused by Alzheimer's disease.
